TB summit 2014: Prevention, diagnosis, and treatment of tuberculosis - A meeting report of a euroscicon conference

Virulence

Volumn 5, Issue 5, 2014, Pages 638-644

  Maitra, Arundhati ^a   Bhakta, Sanjib ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Diagnosis; Dormancy; Drug susceptibility testing; Latency; Mycobacterium; Resistance; Therapeutic targets; Treatment; Tuberculosis; Vaccine

Indexed keywords

ACYLTRANSFERASE; ADALIMUMAB; BCG VACCINE; ISONIAZID; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONAMIDE; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; ANTIBIOTIC RESISTANCE; INCIDENCE; ISOLATION AND PURIFICATION; MYCOBACTERIUM TUBERCULOSIS; SURVIVAL ANALYSIS;

DRUG RESISTANCE, BACTERIAL; HUMANS; INCIDENCE; MYCOBACTERIUM TUBERCULOSIS; SURVIVAL ANALYSIS; TUBERCULOSIS;

EID: 84904189056     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.29803     Document Type: Article

References (52)

1. Maitra A, Bhakta S. Mycobacterium tuberculosis... Can we beat it? Report from a Euroscicon conference 2013. Virulence 2013; 4:499-503 PMID:23863609; http://dx.doi.org/10.4161/viru.25397
2. Kirby T. Tuberculosis rates unacceptably high in UK cities. Lancet Infect Dis 2013; 13:836-7 PM I D: 2 419 92 29; http://dx.doi.org/10.1016/S1473-3099(13)70276-7
3. Organization WH. Global tuberculosis report 2013. World Health Organization, 2013.
4. Shilova MV, Dye C. The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond B Biol Sci 2001; 356:1069-75 PMID: 11516384; http://dx.doi.org/10.1098/rstb.2001.0895
5. Ivanyi J. Could active case finding reduce the transmission of tuberculosis? Lancet 2014; 383:1035-6 PMID:24656191; http://dx.doi.org/10.1016/S0140-6736(14)60510-9
6. Ivanyi J. Serodiagnosis of tuberculosis: due to shift track. Tuberculosis (Edinb) 2012; 92:31-7 PMID:21930430; http://dx.doi.org/10.1016/j.tube.2011.09.001
7. Supply P, Lesjean S, Savine E, Kremer K, van Soolingen D, Locht C. Automated high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis based on mycobacte-rial interspersed repetitive units. J Clin Microbiol 2001; 39:3563-71 PMID:11574573; http://dx.doi.org/10.1128/JCM.39.10.3563-3571.2001
8. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AVS. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005; 85: 47-52 PMID: 15687027; http://dx.doi.org/10.1016/j.tube.2004.09.015
9. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, et al.; MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381:1021-8 PMID:23391465; http://dx.doi.org/10.1016/S0140-6736(13)60177-4
10. Schoolnik GK. Microarray analysis of bacterial pathogenicity. Adv Microb Physiol 2002; 46:1-45 PMID:12073651; http://dx.doi.org/10.1016/S0065-2911(02)46001-8
11. Park H.-D., Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, Schoolnik GK, Sherman DR. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 2003; 48:833-43 PMID:12694625; http://dx.doi.org/10.1046/j.1365-2958.2003.03474.x
12. Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, Voskuil MI, Weldingh K, Andersen P, Schoolnik GK, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006; 8:2052-60 PMID:16931093; http://dx.doi.org/10.1016/j.micinf.2006.03.018
13. Commandeur S, van Meijgaarden KE, Prins C, Pichugin AV, Dijkman K, van den Eeden SJ, Friggen AH, Franken KL, Dolganov G, Kramnik I, et al. An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection. J Immunol 2013; 190:1659-71 PMID:23319735; http://dx.doi.org/10.4049/jimmunol.1201593
14. Pitman R, Jarman B, Coker R. Tuberculosis transmission and the impact of intervention on the incidence of infection. Int J Tuberc Lung Dis 2002; 6:485-91 PMID:12068980
15. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, Lugos MD, Donkor SA, Adetifa IM, de Jong BC, Aiken AM, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 2007; 4:e192 PMID:17564487; http://dx.doi.org/10.1371/journal.pmed.0040192
16. Hill PC, Jackson-Sillah DJ, Fox A, Brookes RH, de Jong BC, Lugos MD, Adetifa IM, Donkor SA, Aiken AM, Howie SR, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 2008; 3:e1379 PMID:18167540; http://dx.doi.org/10.1371/journal.pone.0001379
17. den Hertog AL, Mayboroda OA, Klatser PR, Anthony RM. Simple rapid near-patient diagnostics for tuberculosis remain elusive--is a "treat-to-test" strategy more realistic? PLoS Pathog 2011; 7:e1002207 PMID:22072958; http://dx.doi.org/10.1371/jour-nal.ppat.1002207
18. Rüfenacht S, Bögli-Stuber K, Bodmer T, Jaunin VF, Jmaa DC, Gunn-Moore DA. Mycobacterium microti infection in the cat: a case report, literature review and recent clinical experience. J Feline Med Surg 2011; 13:195-204 PMID:21338944; http://dx.doi.org/10.1016/j.jfms.2011.01.012
19. Gunn-Moore D. Feline tuberculosis caused by Mycobacterium bovis. Vet Rec 2014; 174:322-3 PMID:24676262; http://dx.doi.org/10.1136/vr.g2338
20. Rhodes SG, Gunn-Mooore D, Boschiroli ML, Schiller I, Esfandiari J, Greenwald R, Lyashchenko KP. Comparative study of IFNγ and antibody tests for feline tuberculosis. Vet Immunol Immunopathol 2 011; 14 4: 129-134 PMID: 21906820; http://dx.doi.org/10.1016/j.vetimm.2011.07.020
21. Rhodes S, Holder T, Clifford D, Dexter I, Brewer J, Smith N, Waring L, Crawshaw T, Gillgan S, Lyashchenko K, et al. Evaluation of gamma interferon and antibody tuberculosis tests in alpacas. Clin Vaccine Immunol 2012; 19:1677-83 PMID:22914362; http://dx.doi.org/10.1128/CVI.00405-12
22. Marei AM, El-Behedy EM, Mohtady HA, Afify AF. Evaluation of a rapid bacteriophage-based method for the detection of Mycobacterium tuberculosis in clinical samples. J Med Microbiol 2003; 52:331-5 PMID:12676872; http://dx.doi.org/10.1099/jmm.0.05091-0
23. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121:939-49 PMID: 6774638
24. Guzman JD, Evangelopoulos D, Gupta A, Birchall K, Mwaigwisya S, Saxty B, McHugh TD, Gibbons S, Malkinson J, Bhakta S. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 2013; 3:e002672 PMID:23794563; http://dx.doi.org/10.1136/bmjopen-2013-002672
25. Evangelopoulos D, Bhakta S. Rapid methods for testing inhibitors of mycobacterial growth. Antibiotic Resistance Protocols: Springer, 2010:193-201.
26. Gupta A, Bhakta S, Kundu S, Gupta M, Srivastava BS, Srivastava R. Fast-growing, non-infectious and intra-cellularly surviving drug-resistant Mycobacterium aurum: a model for high-throughput antituber-culosis drug screening. J Antimicrob Chemother 2009; 6 4:774-81 PMID:19656786; http://dx.doi.org/10.1093/jac/dkp279
27. Gupta A, Bhakta S. An integrated surrogate model for screening of drugs against Mycobacterium tuberculosis. J Antimicrob Chemother 2012; 67:1380-91 PMID:22398649; http://dx.doi.org/10.1093/jac/dks056
28. Basavannacharya C, Robertson G, Munshi T, Keep NH, Bhakta S. ATP-dependent MurE ligase in Mycobacterium tuberculosis: biochemical and structural characterisation. Tuberculosis (Edinb) 2010; 90:16-24 PMID:19945347; http://dx.doi.org/10.1016/j.tube.2009.10.007
29. Munshi T, Gupta A, Evangelopoulos D, Guzman JD, Gibbons S, Keep NH, Bhakta S. Characterisation of ATP-dependent Mur ligases involved in the biogenesis of cell wall peptidoglycan in Mycobacterium tuberculosis. PLoS One 2013; 8:e60143 PMID:23555903; http://dx.doi.org/10.1371/journal.pone.0060143
30. Lee W, VanderVen BC, Fahey RJ, Russell DG. Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress. J Biol Chem 2013; 288:6788-800 PMID:23306194; http://dx.doi.org/10.1074/jbc.M112.445056
31. Lack NA, Yam KC, Lowe ED, Horsman GP, Owen RL, Sim E, Eltis LD. Characterization of a carbon-carbon hydrolase from Mycobacterium tuberculosis involved in cholesterol metabolism. J Biol Chem 2010; 285:434-43 PMID:19875455; http://dx.doi.org/10.1074/jbc.M109.058081
32. Payton M, Auty R, Delgoda R, Everett M, Sim E. Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smeg-matis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance. J Bacteriol 1999; 181:1343-7 PMID:9973365
33. Sim E, Sandy J, Evangelopoulos D, Fullam E, Bhakta S, Westwood I, Krylova A, Lack N, Noble M. Arylamine N-acetyltransferases in mycobacteria. Curr Drug Metab 2008; 9:510-9 PMID:18680471; http://dx.doi.org/10.2174/138920008784892100
34. Bhakta S, Besra GS, Upton AM, Parish T, Sholto-Douglas-Vernon C, Gibson KJ, Knutton S, Gordon S, DaSilva R P, Anderton MC, et al. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. J Exp Med 2004; 19 9:1191-9 PMID:15117974; http://dx.doi.org/10.1084/jem.20031956
35. Westwood IM, Bhakta S, Russell AJ, Fullam E, Anderton MC, Kawamura A, Mulvaney AW, Vickers RJ, Bhowruth V, Besra GS, et al. Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars. Protein Cell 2010; 1:82-95 PMID:21204000; http://dx.doi.org/10.1007/s13238-010-0006-1
36. Abuhammad A, Fullam E, Lowe ED, Staunton D, Kawamura A, Westwood IM, Bhakta S, Garner AC, Wilson DL, Seden PT, et al. Piperidinols that show anti-tubercular activity as inhibitors of arylamine N-acetyltransferase: an essential enzyme for myco-bacterial survival inside macrophages. PLoS One 2012; 7:e52790 PMID:23285185; http://dx.doi.org/10.1371/journal.pone.0052790
37. Evangelopoulos D, Cronin N, Daviter T, Sim E, Keep NH, Bhakta S. Characterization of an oxido-reductase from the arylamine N-acetyltransferase operon in Mycobacterium smegmatis. FEBS J 2011; 278:4824-32 PMID:21972977; http://dx.doi.org/10.1111/j.1742-4658.2011.08382.x
38. Chauviac F-X, Bommer M, Yan J, Parkin G, Daviter T, Lowden P, Raven EL, Thalassinos K, Keep NH. Crystal structure of reduced MsAcg, a putative nitro-reductase from Mycobacterium smegmatis and a close homologue of Mycobacterium tuberculosis Acg. J Biol Chem 2012; 287:44372-83 PMID:23148223; http://dx.doi.org/10.1074/jbc.M112.406264
39. Guzman JD, Gupta A, Bucar F, Gibbons S, Bhakta S. Antimycobacterials from natural sources: ancient times, antibiotic era and novel scaffolds. Front Biosci (Landmark Ed) 2012; 17:1861-81 PMID:22201841; http://dx.doi.org/10.2741/4024
40. Guzman JD, Evangelopoulos D, Gupta A, Prieto JM, Gibbons S, Bhakta S. Antimycobacterials from lovage root (Ligusticum officinale Koch). Phytother Res 2013; 27:993-8 PMID:22899555; http://dx.doi.org/10.1002/ptr.4823
41. Kottakota SK, Evangelopoulos D, Alnimr A, Bhakta S, McHugh TD, Gray M, Groundwater PW, Marrs EC, Perry JD, Spilling CD, et al. Synthesis and biological evaluation of purpurealidin E-derived marine sponge metabolites: aplysamine-2, aplyzanzine A, and suberedamines A and B. J Nat Prod 2012; 75:1090-101 PMID:22620987; http://dx.doi.org/10.1021/np300102z
42. Osman K, Evangelopoulos D, Basavannacharya C, Gupta A, McHugh TD, Bhakta S, Gibbons S. An antibacterial from Hypericum acmosepalum inhibits ATP-dependent MurE ligase from Mycobacterium tuberculosis. Int J Antimicrob Agents 2012; 39:124-9 PMID:22079533; http://dx.doi.org/10.1016/j.ijantimicag.2011.09.018
43. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013; 208:199-202 PMID:23564636; http://dx.doi.org/10.1093/infdis/jit152
44. Yin Z, Wang Y, Whittell LR, Jergic S, Liu M, Harry E, Dixon NE, Kelso MJ, Beck JL, Oakley AJ. DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem Biol 2014; 21: 481-7 PMID:24631121; http://dx.doi.org/10.1016/j.chembiol.2014.02.009
45. Burki T. Improving the health of the tuberculosis drug pipeline. Lancet Infect Dis 2014; 14:102-3 PMID:24605379; http://dx.doi.org/10.1016/S1473-3099(14)70006-4
46. Mahajan R. Bedaquiline: First FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res 2013; 3:1-2 PMID:23776831; http://dx.doi.org/10.4103/2229-516X.112228
47. Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: Promises and pitfalls. Tuberculosis (Edinb) 2014; 94:357-62 PMID:24841672; http://dx.doi.org/10.1016/j.tube.2014.04.001
48. Tsuyuguchi K, Matsumoto T. Biologics and myco-bacterial diseases]. Kekkaku 2013; 88:337-53 PMID:23672175
49. Kulchavenya E, Kim C-S, Bulanova O, Zhukova I. Male genital tuberculosis: epidemiology and diagnostic. World J Urol 2012; 30:15-21 PMID:21604018; http://dx.doi.org/10.1007/s00345-011-0695-y
50. Kulchavenya E, Zhukova I, Kholtobin D. Spectrum of urogenital tuberculosis. J Infect Chemother 2013; 19:880-3 PMID:23526041; http://dx.doi.org/10.1007/s10156-013-0586-9
51. Rozati R, Roopa S, Rajeshwari CN. Evaluation of women with infertility and genital tuberculosis. J Obstet Gynaecol India 2006; 56:423-6
52. Kulchavenya E. Best practice in the diagnosis and management of urogenital tuberculosis. Ther Adv Urol 2013; 5:143-51 PMID:23730329; http://dx.doi.org/10.1177/1756287213476128